Clinical trials: COVID-19 Convalescent Plasma Treatment
Covid-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
- Trial name
- Inova-CCP (NCT04502472)
- Testing
- Convalescent plasma transfusion
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Inova Health Care Services
COVID-19
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease.
- Trial name
- PLASCOSSA (NCT04372979)
- Testing
- Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Covid19
Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort
The coronavirus disease 2019 (COVID-19) viral pneumonia is now a worldwide pandemic caused by the Severe acute respiratory virus coronavirus 2 (SARS-CoV-2).
- Trial name
- CORIPLASM (NCT04345991)
- Testing
- Transfusion of COVID-19 convalescent plasma
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID19, Coronavirus Infection
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements.
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases
- Trial name
- NCT04376034
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- West Virginia University
COVID
Convalescent Plasma in Pediatric COVID-19
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high…
- Trial name
- NCT04458363
- Testing
- Convalescent Plasma (CP), Standard COVID-19 therapies
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Severe COVID-19 Disease
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease
Currently, there is no specific treatment or vaccine for SARS-CoV-2 available, some drugs are being investigated as treatment, but the effect is unknown.
- Trial name
- PC-COVID-HCM (NCT04542967)
- Testing
- Biological
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Hospital Central Militar
Covid19
Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19
Multicenter retrospective cohort study from June to August 2020 on hospitalized COVID-19 patients admitted to Al-Hakeem and Al-Amal hospital in Al-Najaf Governorate, Iraq, in order to evaluating the effectiveness of plasma…
- Trial name
- NCT04764747
- Where
- 2 sites in Iraq
- Volunteers
- 400 people
- Sponsor
- Kufa University
COVID-19
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in…
- Trial name
- NCT04434131
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of New Mexico
SARS-CoV 2
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.
- Trial name
- NCT04366245
- Testing
- Hyperimmune plasma, Standard of care for SARS-CoV-2 infection
- Where
- 14 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Andalusian Network for Design and Translation of Advanced Therapies
SARS-CoV-2 Infection, Safety and Efficacy
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19…
- Trial name
- NCT04621123
- Testing
- Convalescent anti-SARS-CoV-2 MBT plasma, Control Group
- Where
- 4 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
COVID-19
SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients
Severe and critically ill patients will be enrolled in the study (50 patients) after duly filled consent forms. Recipients shall be divided in to 5 groups with 10 patients per group to compare clinical efficacy and safety of…
- Trial name
- NCT04521309
- Testing
- SARS-CoV-2 antibody based IVIG therapy
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Dow University of Health Sciences
COVID-19 Convalescent Plasma Treatment
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more…
- Trial name
- Covid-IC (NCT05905380)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Convalescent Plasma Treatment
COVID-19 With Convalescent Plasma
To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.
- Trial name
- NCT04616976
- Testing
- convalescent plasma
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Southeast University, China
COVID-19
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness.
- Trial name
- NCT04390178
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Joakim Dillner
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
COVID-19
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon…
- Trial name
- ConCoVid-19 (NCT04342182)
- Testing
- Convalescent plasma
- Where
- 18 sites in Netherlands
- Volunteers
- 86 people
- Sponsor
- Erasmus Medical Center
COVID-19, SARS-CoV 2
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19
The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients.
- Conditions
- COVID-19, SARS-CoV 2, Convalescence, Plasma
- Trial name
- COPLASCOV19 (NCT04356482)
- Testing
- convalescent plasma
- Where
- 3 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
COVID-19 Pneumonia
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia
Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared pandemic on March 2020.
- Trial name
- NCT04381858
- Testing
- Plasma from COVID-19 convalescent patient, Human immunoglobulin
- Where
- Mexico
- Volunteers
- 196 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
Acute Respiratory Distress Syndrome
Effectiveness of Convalescent Immune Plasma Therapy
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
- Trial name
- NCT04442958
- Testing
- Convalescent Immune Plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Bagcilar Training and Research Hospital